Dr Pavan Bhargava gives insights on earlier diagnosis, ocrelizumab safety in pregnancy, and promising anti-aging effects of diet in RRMS.

A University of Alberta study shows that rural Albertans living with multiple sclerosis are not as likely as urban patients to receive the best treatments to prevent relapses and slow down progression ...

Two researchers win the Breakthrough Prize in Life Sciences for their discoveries related to multiple sclerosis disease ...

Tolebrutinib, a novel BTK inhibitor that targets neuroinflammation, slowed disability progression by 31% in nrSPMS, a phase 3 ...

That's because Greg, an engineer, rode his bike in the MS 150, a punishing ride, formerly between Houston and Austin. (The ...

Depression and anxiety have been well documented in people with multiple sclerosis (MS), but often are undiagnosed or ...

Investigational tolebrutinib slowed disability progression in people with non-relapsing secondary progressive multiple ...

Marathon runners experience reversible changes in their brain myelin. These findings indicate that myelin (a substance that surrounds the neurons) exhibits behavior that was previously unknown, and ...

Tolebrutinib was found to delay disability progression in people with nonrelapsing secondary progressive MS in a Phase 3 ...

The National Multiple Sclerosis society funds research, drives change through advocacy and provides programs and resources to help people affected by MS live their best ...

The University of Oregon now has four confirmed international students who have had their visas revoked based on unspecified ...

The findings indicate that the currently approved 600-mg dose of intravenous ocrelizumab is optimal to significantly slow ...